Autolus Therapeutics (AUTL) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed Autolus Therapeutics (AUTL) over the past year, gaining 52.3% versus a gain of 21.5%. Over five years, TECX leads with a -67.4% price change compared with -70.5% for AUTL. Autolus Therapeutics is the larger company by market cap ($481.8 million vs $444.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | TECX |
|---|---|---|
| Share price | $1.81 | $22.71 |
| Market cap | $481.75M | $443.97M |
| 1-day change | +1.12% | +1.34% |
| YTD return | -9.05% | +8.87% |
| 1-year return | +21.48% | +52.31% |
| 5-year return | -70.52% | -67.37% |
| EPS (TTM) | $-1.06 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $39.53 |
| 52-week low | $1.18 | $15.32 |
| Distance from 52-week high | -29.84% | -42.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +382.32% | +237.43% |
| Average volume | 2.10M | 219.12K |
| Shares outstanding | 266.16M | 19.55M |
| Employees | 752 | 60 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed AUTL by 30.8 percentage points over the past year.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Healthcare · Biotechnology · 752 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Healthcare · Biotechnology · 60 employees
AUTL vs TECX FAQ
Which is bigger, Autolus Therapeutics or Tectonic Therapeutic?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $481.75M compared with $443.97M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, AUTL or TECX?
TECX returned +52.31% over the past 12 months, compared with +21.48% for AUTL (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.